Role of Surgery in Combined Treatment at Stage III
-
Upload
shay-farmer -
Category
Documents
-
view
33 -
download
4
description
Transcript of Role of Surgery in Combined Treatment at Stage III
Marmara University School of Medicine Dept of Thoracic Surgery
Role of Surgery in Combined Treatment at
Stage III
Asso.Prof.Hasan F.Batırel
Marmara University School of Medicine Dept of Thoracic Surgery
• Stage III disease
• Role of surgery in Stage III NSCLC
• Results of studies
• Current problems and solutions
• Conclusion
Marmara University School of Medicine Dept of Thoracic Surgery
Stage III Disease
• Stage III disease according to the 1997 system.
• IIIA ve IIIB
• Before 1997 different staging system and results in series (T3N0).
Marmara University School of Medicine Dept of Thoracic Surgery
Which Stages?
Stage IIIA – T3N1, T1-3N2Stage IIIB – T4N0
Stage IIIB – T1-4N3
Marmara University School of Medicine Dept of Thoracic Surgery
Evolution of Surgery
• 1982 Pearson – Cervical mediastinoscopy
• Poor survival in N2 + pations 9% 5 yr survival (Pearson – 1982), 16% (Naruke – 1988)
• So locoregional disease?
Marmara University School of Medicine Dept of Thoracic Surgery
Multimodal Treatments
• Starting multimodality trials
• 2 small series (60 pts each) by Roth and Rosell 1994.
• Surgery + Adj / Neoadj Chemo + Surgery + Adj
Marmara University School of Medicine Dept of Thoracic Surgery
The Type of Preoperative Treatment• Chemotherapy – CALGB 8935
Sugarbaker 1995.
• Chemoradiation – SWOG 8805 Albain 1995.
Marmara University School of Medicine Dept of Thoracic Surgery
No role for surgery?
• Albain 2005 – INT 0139/RTOG 9309
• Van Meerbeck 2007 – EORTC 08941
Marmara University School of Medicine Dept of Thoracic Surgery
Pearson ve Naruke
Pearson 1982
• N2+ diagnosed preop, 5 yr survival 9% (n=79).
• N2+ found during surgery, 5 yr survival %24 (n=62).
Naruke 1988
• Clinical N2 disease, 5 yr survival 16% (n=345)
Marmara University School of Medicine Dept of Thoracic Surgery
Roth and Rosell Studies
• 60 patients each
• T3N0 included in each series.
• Routine mediastinoscopy only in Roth study.
• Roth 36% vs 15% 5 yr survival.
• Rosell 17% vs 0% 5 yr survival.
Marmara University School of Medicine Dept of Thoracic Surgery
Survival advantage continues at 7-8 year follow-up.
Marmara University School of Medicine Dept of Thoracic Surgery
Type of Preoperative Treatment
• CALGB 8935 – Sugarbaker 1995, Neoadj Chemo + Surgery + Adj XRT Pathologic partial response 22%.
• SWOG 8805 – Albain 1995, Concurrent Neoadj CRT, Surgery, Pathologic complete response 21%, Lymph node clearance 59%.
• 3 year survival 23% ve 26%.
Marmara University School of Medicine Dept of Thoracic Surgery
SWOG 8805
• Even in the case of radiologically and clinical stable disease %25 pathologic complete response!!!
• One of the most important findings to show the weaknesses of radiologic re-staging following neoadjuvant treatment…
Marmara University School of Medicine Dept of Thoracic Surgery
Metaanalysis – Stage III
Neoadjuvant• Bergmans, Lung Cancer 2005.
Marmara University School of Medicine Dept of Thoracic Surgery
EORTC – 08941 – JNCI 2007• %90 partial response, %7 pathologic complete
response• %47 pneumonectomy
Marmara University School of Medicine Dept of Thoracic Surgery
Issues with EORTC and INT studies
• The number of accrual is insufficient to show small differences.
• The percent of pneumonectomies is very high in the EORTC study.
• Long-term results of Intergroup study will be clinically important.
Marmara University School of Medicine Dept of Thoracic Surgery
Pneumonectomy following Neoadjuvant Treatment
• Martin MSKCC 2001 Ann Thorac Surg - %11 (right side %26).
• Albain INT 0139 2005 JCO - %26 (right side %39).
• EORTC 08941 2007 JNCI - %7 (right side %5).
Marmara University School of Medicine Dept of Thoracic Surgery
Survival in Patients with Lymph
Node Downstaging
• CALGB 8935 – J Surg Oncol 2006. N0 patients 47.8, N2 patients 8.2 months.
• Van Schil – EJCTS 2006. N0 patients 41, N2 patients 7 ay. Remediastinoscopy recommended.
• Bueno – Ann Thorac Surg 2000. N0 patients 21.3, N2 patients 15.9 months. 5 year survival 36% vs 9%.
Marmara University School of Medicine Dept of Thoracic Surgery
Lymph Node and Primary Tumor Response
Marmara University School of Medicine Dept of Thoracic Surgery
Staging Following Neoadjuvant Treatment
• Remediastinoscopy,
VAMLA
• VATS
• Transbronchial USG
• PET
Marmara University School of Medicine Dept of Thoracic Surgery
Pathologic Complete/Partial Response
• PET during neoadjuvant treatment?
• Concurrent Chemotx + RT
• Evaluation of complete response – Surgical specimen
Marmara University School of Medicine Dept of Thoracic Surgery
• N2 Stage IIIA NSCLC Surgery following neoadjuvant treatment > Surgery alone.
• Persistence of N2 disease following neoadjuvant treatment – Surgery < Curative CRT
Lessons Learned During Evolution of Surgery – 1
Marmara University School of Medicine Dept of Thoracic Surgery
Lessons Learned During Evolution of Surgery– 2
• Pneumonectomy required following neoadjuvant tx - Surgery < Curative CRT
• Lymph node downstaging, resectable with lobectomy – Surgery offers excellent long term local control and survival when compared with other modalities.
Marmara University School of Medicine Dept of Thoracic Surgery
Conclusion
• The boundaries and role of surgery is becoming more apparent in Stage IIIA NSCLC.
• This patient group will probably be stratified to microscopic systemic and locally limited (not locally invasive) disease via molecular/pathologic markers.
• There is no doubt that surgery is the best treatment in locally limited disease.